Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1516575 | 0.98 | KMT2A (0.40) | KMT2AHTTPIK3C3OPRK1MEN1 | |
| SCHEMBL857401 | 0.84 | PIK3C3 (0.48) | KMT2AHTTPIK3C3OPRK1KDM4E | |
| SCHEMBL21591708 | 0.83 | OPRK1 (0.37) | KMT2APIK3C3OPRK1MEN1TDP1 | |
| SCHEMBL30041415 | 0.83 | OPRK1 (0.37) | KMT2APIK3C3OPRK1MEN1TDP1 | |
| SCHEMBL11968535 | 0.83 | NOS3 (0.42) | PIK3C3PIK3CAMTOR | |
| SCHEMBL1599853 | 0.82 | ALDH1A1 (0.40) | KMT2APIK3C3OPRK1MEN1TDP1 | |
| SCHEMBL2628501 | 0.82 | PIK3C3 (0.40) | KMT2APIK3C3OPRK1MEN1TDP1 | |
| SCHEMBL29915138 | 0.82 | ALDH1A1 (0.40) | KMT2APIK3C3OPRK1MEN1TDP1 | |
| SCHEMBL19100681 | 0.79 | PIK3C3 (0.39) | KMT2APIK3C3OPRK1MEN1TDP1 | |
| SCHEMBL23705904 | 0.78 | PIK3CA (0.35) | KMT2APIK3C3OPRK1MEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC | 2023-05-11 | — | — | US | disclosed |
| CN-115835909-A | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4146345-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1781654-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2006015123-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143502-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | KMT2A 2205/4885HTT 2855/4885PIK3C3 2955/4885 |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | KMT2A 2205/4885HTT 2855/4885PIK3C3 2955/4885 |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | MAP3K20, MAP4K2, MAP3K19 | KMT2A 1322/4885HTT 2856/4885PIK3C3 595/4885 |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | KMT2A 2205/4885HTT 2855/4885PIK3C3 2955/4885 |
| US-11957689-B2 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | KMT2A 2205/4885HTT 2855/4885PIK3C3 2955/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | KMT2A 975/4885HTT 2554/4885PIK3C3 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.